Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 120

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 120
---
5, 2024, Goodwood Fund, together with its affiliate and control person, became a major
shareholder due to its beneficial ownership of over 5% of our outstanding Common Shares. Based solely on a Schedule 13DA filed on December
20, 2024, Goodwood Fund LP, together with its affiliates and control person, held approximately 8.2% of our outstanding Common Shares
as of December 20, 2024.

United States Shareholders

Based on a review of the information provide to us
by our transfer agent, as at March 26, 2025, there were [14] holders of record of our Common Shares, of which [two] were registered with
an address in the U. S., holding in the aggregate approximately 99% of our outstanding Common Shares. We believe that the number of beneficial
owners of our Common Shares is substantially greater than the number of record holders, because the overwhelming majority of our Common
Shares are held in broker “street names”.

  Related party transactions  
 ──────────────────────────────

During the year ended December 31, 2024, the Company
made payments for research and development expenditures to Angiogenesis Foundation for which a Director of the Company is the CEO of
the Foundation of $50 (2023 - $201 and 2022 - $105). Other than employment agreements and indemnification agreements with our management
as described under “ Item 10. - Additional Information,” there are no further related party transactions.

  Interests of experts and counsel  
 ────────────────────────────────────

Not required.

  Item 8.      Financial Information  
 ──────────────────────────────────────

  Consolidated statements and other financial information  
 ───────────────────────────────────────────────────────────

The consolidated financial statements
filed as part of this Annual Report on Form 20-F are presented under “ Item 18. - Financial Statements”.

  Significant changes  
 ───────────────────────

No significant changes occurred since the date of
our annual consolidated financial statements included elsewhere in this Annual Report on Form 20-F.

  82  

  Item 9.      The Offer and Listing  
 ──────────────────────────────────────

  Offer and listing details  
 ─────────────────────────────

Not applicable, except for Item
9A(4). Our Common Shares have been listed on both the NASDAQ and the TSX under the symbol “ CSCI”. From November 20